Fidelis Capital Partners’s Eli Lilly LLY Stock Holding History

Fidelis Capital Partners’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.9M	Buy	8,594 +254	+3%	+$258K	0.56%	37
2025 Q4	$8.96M	Buy	8,340 +171	+2%	+$164K	0.65%	31
2025 Q3	$6.23M	Buy	8,169 +269	+3%	+$200K	0.49%	40
2025 Q2	$5.9M	Sell	7,900 -55	-0.7%	-$42.7K	0.54%	36
2025 Q1	$7.04M	Buy	7,955 +776	+11%	+$646K	0.75%	30
2024 Q4	$5.82M	Buy	7,179 +236	+3%	+$195K	0.58%	34
2024 Q3	$6.27M	Sell	6,943 -849	-11%	-$763K	0.75%	27
2024 Q2	$6.02M	Sell	7,792 -297	-4%	-$238K	0.86%	25
2024 Q1	$6.29M	Buy	8,089 +2,004	+33%	+$1.43M	0.96%	22
2023 Q4	$3.55M	Buy	6,085 +1,385	+29%	+$808K	0.78%	25
2023 Q3	$2.52M	Buy	4,700 +367	+8%	+$189K	0.86%	20
2023 Q2	$2.03M	Buy	4,333 +224	+5%	+$93.9K	0.74%	28
2023 Q1	$1.76M	Buy	4,109 +2,276	+124%	+$768K	0.75%	27
2022 Q4	$641K	Buy	+1,833	New	+$650K	0.76%	39

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelis Capital Partners's LLY Position: Q1 2026 in Review

Fidelis Capital Partners increased its Eli Lilly (LLY) stake by 3% in Q1 2026, buying an estimated $258K and bringing the position to 8,594 shares worth $7.9M. The position accounts for 0.56% of the portfolio, ranked #37.

Fidelis Capital Partners first reported a position in LLY in Q4 2022 and has held it in 14 quarters since. The position peaked at $8.96M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Fidelis Capital Partners held 8,594 shares of Eli Lilly worth $7.9M as of Q1 2026.
Fidelis Capital Partners bought 254 Eli Lilly shares in Q1 2026, an estimated $258K.
Eli Lilly made up 0.56% of Fidelis Capital Partners's portfolio in Q1 2026, its #37 holding.
Fidelis Capital Partners first reported a position in Eli Lilly in Q4 2022 and has held it in 14 quarters since.
Fidelis Capital Partners's Eli Lilly position peaked at $8.96M in Q4 2025.
4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Fidelis Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.